| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
MEDP Stock Overview
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
Medpace Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$182.30 |
| 52 Week High | US$231.00 |
| 52 Week Low | US$126.95 |
| Beta | 1.43 |
| 1 Month Change | 23.19% |
| 3 Month Change | 30.65% |
| 1 Year Change | 2.59% |
| 3 Year Change | 130.76% |
| 5 Year Change | 484.30% |
| Change since IPO | 550.14% |
Recent News & Updates
We Think Medpace Holdings (NASDAQ:MEDP) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Medpace 2022 revenue guidance above consensus estimate as Q2 beats on top, bottom lines
Medpace Holdings (NASDAQ:MEDP) is projecting 2022 revenue of $1.405B-$1.435B, above the current consensus of $1.4B. The contract research organization is also guiding to GAAP EPS for the year of $6.07-$6.36. Consensus is $6.12. Medpace (MEDP) released its 2022 guidance as it released its Q2 results after the closing bell Monday, beating on both the top and bottom lines. Net income of ~$49.4M was a ~24% increased compared to Q2 2022 ($1.52 vs. $1.11 basic, and $1.46 vs. $1.06 diluted EPS). Q2 revenue of $351.21M was a ~26% year-over-year increase. Medpace (MEDP) noted that new business awards of $450.6M was a ~16% increase from the prior-year period. The company ended the quarter with $42.6M of cash and cash equivalents. Seeking Alpha's Quant Rating with high marks for profitability, momentum and revisions.
Is Medpace Holdings, Inc. (NASDAQ:MEDP) Potentially Undervalued?
Medpace Holdings, Inc. ( NASDAQ:MEDP ), is not the largest company out there, but it saw a decent share price growth in...
Shareholder Returns
| MEDP | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 10.0% | 1.9% | 3.2% |
| 1Y | 2.6% | -19.8% | -10.2% |
Return vs Industry: MEDP exceeded the US Life Sciences industry which returned -19.8% over the past year.
Return vs Market: MEDP exceeded the US Market which returned -10.1% over the past year.
Price Volatility
| MEDP volatility | |
|---|---|
| MEDP Average Weekly Movement | 6.5% |
| Life Sciences Industry Average Movement | 11.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MEDP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MEDP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 4,800 | August Troendle | https://www.medpace.com |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medpace Holdings Fundamentals Summary
| MEDP fundamental statistics | |
|---|---|
| Market Cap | US$5.65b |
| Earnings (TTM) | US$209.02m |
| Revenue (TTM) | US$1.29b |
27.0x
P/E Ratio4.4x
P/S RatioIs MEDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDP income statement (TTM) | |
|---|---|
| Revenue | US$1.29b |
| Cost of Revenue | US$489.02m |
| Gross Profit | US$797.25m |
| Other Expenses | US$588.23m |
| Earnings | US$209.02m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.74 |
| Gross Margin | 61.98% |
| Net Profit Margin | 16.25% |
| Debt/Equity Ratio | 88.2% |
How did MEDP perform over the long term?
See historical performance and comparisonValuation
Is MEDP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MEDP?
Other financial metrics that can be useful for relative valuation.
| What is MEDP's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$5.65b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.7x |
| Enterprise Value/EBITDA | 23.6x |
| PEG Ratio | 2.9x |
Price to Earnings Ratio vs Peers
How does MEDP's PE Ratio compare to its peers?
| MEDP PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 31.1x | ||
SHC Sotera Health | 46x | 32.9% | US$5.7b |
SYNH Syneos Health | 25.4x | 17.4% | US$7.1b |
STVN Stevanato Group | 38.7x | 8.3% | US$4.8b |
MRVI Maravai LifeSciences Holdings | 14.1x | -6.1% | US$6.8b |
MEDP Medpace Holdings | 27x | 9.3% | US$5.7b |
Price-To-Earnings vs Peers: MEDP is good value based on its Price-To-Earnings Ratio (27x) compared to the peer average (31.1x).
Price to Earnings Ratio vs Industry
How does MEDP's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Earnings vs Industry: MEDP is good value based on its Price-To-Earnings Ratio (27x) compared to the US Life Sciences industry average (32.6x)
Price to Earnings Ratio vs Fair Ratio
What is MEDP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 27x |
| Fair PE Ratio | 23.5x |
Price-To-Earnings vs Fair Ratio: MEDP is expensive based on its Price-To-Earnings Ratio (27x) compared to the estimated Fair Price-To-Earnings Ratio (23.5x).
Share Price vs Fair Value
What is the Fair Price of MEDP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MEDP ($182.3) is trading below our estimate of fair value ($219.24)
Significantly Below Fair Value: MEDP is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Future Growth
How is Medpace Holdings forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
9.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEDP's forecast earnings growth (9.3% per year) is above the savings rate (1.9%).
Earnings vs Market: MEDP's earnings (9.3% per year) are forecast to grow slower than the US market (14.4% per year).
High Growth Earnings: MEDP's earnings are forecast to grow, but not significantly.
Revenue vs Market: MEDP's revenue (13.1% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: MEDP's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MEDP's Return on Equity is forecast to be very high in 3 years time (40.8%).
Discover growth companies
Past Performance
How has Medpace Holdings performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
34.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MEDP has high quality earnings.
Growing Profit Margin: MEDP's current net profit margins (16.3%) are lower than last year (17%).
Past Earnings Growth Analysis
Earnings Trend: MEDP's earnings have grown significantly by 34.6% per year over the past 5 years.
Accelerating Growth: MEDP's earnings growth over the past year (19.5%) is below its 5-year average (34.6% per year).
Earnings vs Industry: MEDP earnings growth over the past year (19.5%) exceeded the Life Sciences industry 15.6%.
Return on Equity
High ROE: MEDP's Return on Equity (73.9%) is considered outstanding.
Discover strong past performing companies
Financial Health
How is Medpace Holdings's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: MEDP's short term assets ($328.9M) do not cover its short term liabilities ($879.0M).
Long Term Liabilities: MEDP's short term assets ($328.9M) exceed its long term liabilities ($153.2M).
Debt to Equity History and Analysis
Debt Level: MEDP's net debt to equity ratio (73.1%) is considered high.
Reducing Debt: MEDP's debt to equity ratio has increased from 25.7% to 88.2% over the past 5 years.
Debt Coverage: MEDP's debt is well covered by operating cash flow (114.6%).
Interest Coverage: MEDP's interest payments on its debt are well covered by EBIT (417.6x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Medpace Holdings's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MEDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MEDP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MEDP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MEDP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MEDP has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.5yrs
Average management tenure
CEO
August Troendle (66 yo)
30.08yrs
Tenure
US$5,947,423
Compensation
Dr. August James Troendle, M.D. has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1992 until August 01, 2021. Dr. Troendle foun...
CEO Compensation Analysis
Compensation vs Market: August's total compensation ($USD5.95M) is about average for companies of similar size in the US market ($USD8.19M).
Compensation vs Earnings: August's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: MEDP's management team is considered experienced (4.5 years average tenure).
Board Members
Experienced Board: MEDP's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Medpace Holdings, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Medpace Holdings, Inc.
- Ticker: MEDP
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.651b
- Shares outstanding: 31.00m
- Website: https://www.medpace.com
Number of Employees
Location
- Medpace Holdings, Inc.
- 5375 Medpace Way
- Cincinnati
- Ohio
- 45227
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/13 00:00 |
| End of Day Share Price | 2022/08/12 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.